CPRX
Catalyst Pharmaceuticals Inc
31.50$
+0.0%
vs. previous close
Closing price · As of: Jul 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +36.9% | -30.6% | +104.7% | -29.2% | +85.9% | +71.2% | +23.6% | +58.0% | +25.2% | +81.1% | +30.0% | |
| – | +36.7% | -30.8% | +105.5% | -35.2% | +101.8% | +43.0% | +31.9% | +52.7% | -31.6% | +184.3% | +43.4% | |
| – | +210.4% | -50.8% | +313.9% | -71.2% | +440.5% | +45.5% | +31.6% | +74.0% | -53.9% | +276.0% | +37.0% | |
| – | +48.7% | -30.8% | +107.9% | -36.3% | +76.7% | +48.4% | +36.3% | +56.0% | -53.9% | +276.0% | +37.0% | |
| – | – | – | – | – | – | -43.2% | +12.3% | +60.5% | +395.8% | +22.4% | +95.9% | |
| – | – | – | – | – | +3,393.5% | +137.7% | +69.2% | -13.5% | +129.9% | +24.9% | +90.2% | |
| – | +168.4% | +27.5% | -21.6% | +28.2% | -14.2% | -38.3% | +2,963.2% | -78.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +497.6% | -19.3% | -16.0% | |
| – | -46.6% | -48.2% | +84.5% | +118.5% | +156.0% | -8.0% | +36.0% | +142.9% | +9.3% | +50.5% | +23.2% | |
| – | -41.2% | -39.1% | +103.7% | +122.9% | +153.4% | -5.6% | +18.9% | +112.8% | +32.1% | +58.7% | +21.9% | |
| – | – | – | – | – | – | -90.3% | +962.1% | +9.4% | +9.5% | +8.9% | +8.7% | |
| – | -1.1% | -48.0% | +108.5% | +20.1% | +76.2% | +3.4% | -35.0% | +43.6% | +272.2% | +12.2% | -32.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +57.4% | -29.1% | +106.0% | -37.3% | +72.6% | +93.5% | +22.0% | +45.2% | +29.1% | +87.6% | +31.1% | |
| – | – | – | – | – | – | – | – | – | +143.2% | +135.1% | +66.3% | |
| – | +26.1% | +2.5% | +3.5% | +19.6% | +3.3% | +0.2% | +1.5% | +3.3% | +2.1% | +9.8% | +1.9% |
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.